Background: There are limited data regarding the effect of long-standing hyperglycemia on the occurrence of acute kidney injury (AKI) in ST segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). Methods: We retrospectively studied 723 STEMI patients undergoing primary PCI. Patients were stratified into two groups according to glycated hemoglobin (HbA1c) levels as a marker of prolonged hyperglycemia: those with HbA1c < 7% and those with HbA1c ≥7%. Medical records were reviewed for the occurrence of AKI. Results: HbA1c levels ≥7% were found in 225/723 (31%) of patients. The occurrence of AKI was significantly higher among patients with HbA1c levels ≥7% (32/225, 14%) compared to patients with HbA1c levels < 7% (32/498, 6%; p = 0.001). Patients with chronic kidney disease (CKD) and HbA1c ≥7% had an eight-fold increase in the incidence of AKI compared to patients with HbA1c < 7% and no CKD (32 vs. 4%). In a multivariable regression model, HbA1c ≥7% was independently associated with AKI (OR 1.92, 95% CI 1.09-3.36, p = 0.02). Conclusion: HbA1c ≥7% was associated with a higher likelihood of AKI in STEMI patients treated with primary PCI.
Introduction
Acute kidney injury (AKI) frequently complicates the course of ST segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) and is associated with adverse short-and long-term outcomes [1] [2] [3] [4] . The worsening renal function may be a result of various factors, including contrast-induced AKI (CI-AKI) [5] [6] [7] , reduced renal perfusion, and other metabolic factors [8] [9] [10] . Previous studies have shown that elevated glucose levels upon hospital admission increase the risk of contrastinduced nephropathy in patients undergoing elective [11, 12] and primary PCI [10, 13] ; however, only limited data are present regarding the effect of long-standing hyperglycemia on AKI in STEMI patients undergoing primary PCI. In the present study we evaluated the association of long-term glycemic control (using glycated hemoglobin [HbA1c] as a marker of glucose control in the last 2-3 months) on the occurrence of AKI in a large cohort of STEMI patients treated with primary PCI.
Methods

Study Design
We performed a retrospective, single-center observational study at the Tel Aviv Sourasky Medical Center, a tertiary referral hospital with a 24/7 primary PCI service.
Study Population (Fig. 1)
Included were all patients admitted between January 2014 and August 2017 to the cardiac intensive care unit with a diagnosis of acute STEMI and treated with primary PCI. Patients were recognized as having diabetes mellitus (DM) if they had previously been diagnosed by a physician or if they received medication to lower blood glucose levels (oral antihyperglycemic agents or any extended-release insulin) [10, 14, 15] . A total of 210 patients in whom information regarding HbA1c was lacking were excluded from the analysis. We also excluded patients who died within 24 h of admission since we presumed there was insufficient time for AKI to occur, as well as patients requiring chronic peritoneal dialysis or hemodialysis treatment. The final study population consisted of 723 patients whose baseline demographics, cardiovascular history, clinical risk factors, treatment characteristics, and laboratory results were all retrieved from the hospital electronic medical records.
Study Procedure
The diagnosis of STEMI was established in accordance with published guidelines including typical chest pain history, diagnostic electrocardiographic changes (ST segment elevation > 1 mm in two contiguous peripheral leads or > 2 mm in two or more contiguous precordial leads or new left bundle branch), and serial elevation of cardiac biomarkers [14] . Primary PCI was performed on patients with symptoms lasting ≤12 h as well as in patients with symptoms lasting 12-24 h if the symptoms persisted at the time of admission and the admission electrocardiogram demonstrated persistent ST segment elevation. Critical state patients were defined as those mechanically ventilated or those in whom intra-aortic balloon counterpulsation was inserted. During the study period, none of these patients were treated with an Impella device or with extracorporeal membrane oxygenation. The contrast medium used in the procedures was iodixanol (Visipaque, GE Healthcare, Ireland) or iohexol (Omnipaque, GE Healthcare). Following coronary interventional procedures, physiologic (0.9%) saline was given intravenously to all patients at a rate of 1 mL/kg/h for 12 h after contrast exposure. In patients with overt heart failure, the hydration rate was reduced at the discretion of the attending physician. All patients underwent a screening echocardiographic examination within 48 h of admission. Left ventricular ejection fraction was calculated by the biplane method of disks (modified Simpson's rule). A 17-segment model was used for scoring the severity of segmental wall motion abnormalities. A random blood glucose level was measured on admission and thus represented the nonfasting level.
HbA1c levels were determined for all patients and included from blood samples taken within 48 h of hospital admission. Patients were stratified into two groups according to HbA1c levels: patients with HbA1c < 7% and patients with HbA1c ≥7%. A cutoff point of 7% was chosen because it is the recommended target of glycemic control for type 2 DM to reduce complications [16] .
The serum creatinine (sCr) level was determined upon hospital admission and at least once a day during the cardiac intensive care unit stay and was available for all analyzed patients. The estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease equation [17] . Chronic kidney disease (CKD) was defined as an admission eGFR of ≤60 mL/min/1.73 m 2 [18] . AKI was determined using the Kidney Disease: Improving Global Outcomes criteria [19] and defined as a sCr rise > 0.3 mg/dL within 48 h of contrast exposure compared with admission sCr.
Statistical Analysis
All data were summarized and displayed as mean ± standard deviation for continuous variables and as number (percentage) of patients in each group for categorical variables. The p values for the categorical variables were calculated with the χ 2 test. Continuous variables were compared using the independent sample t test or with ANOVA. Identification of the independent predictors of AKI was done using the logistic regression model at the enter mode. We adjusted for age, sex, hypertension, left ventricular ejection fraction, critical state, heart failure, time to reperfusion, contrast volume, contrast volume/eGFR ratio, and eGFR ≤60 mL/ min/1.73 m. A two-tailed p value < 0.05 was considered significant for all analyses. All analyses were performed with the SPSS software (SPSS Inc., Chicago, IL, USA).
Results
The study population included 723 patients (mean age 61 ± 12 years, 81% males), 225 of whom (31%) had an HbA1c level ≥7%. The baseline characteristics of the patients according to HbA1c level are presented in Table 1 . Patients with HbA1c levels ≥7% were older and had more comorbidities, with significantly higher admission glucose levels, longer time to reperfusion, and higher C-reactive protein levels. Table 2 compares the sCr changes, the intravenous contrast volume applied, and the occurrence of AKI according to HbA1c levels. Patients having HbA1c levels ≥7% had lower admission eGFR, were more likely to have CKD, and had higher peak sCr levels. The total volume of contrast medium did not differ statistically between the two groups. The occurrence of AKI was significantly higher among patients with HbA1c levels ≥7% (32/225, 14%) compared to patients with HbA1c levels < 7% (32/498, 6%) (p = 0.001).
In univariable analysis, the incidence of AKI was found to be related to baseline CKD. Among patients without CKD, the incidence of AKI in patients with HbA1c ≥7% was two-fold higher than in patients having HbA1c < 7% (8 vs. 4, p = 0.02; Fig. 2 ). Among patients with baseline CKD, there was a numerical difference in the incidence of AKI between patients with HbA1c ≥7% versus patients with HbA1c < 7% that did not reach statistical significance (32 vs. 19%, p = 0.09). Importantly, patients with CKD and HbA1c ≥7% had an eight-fold increase in the incidence of AKI compared to patients with HbA1c < 7% and no CKD (Fig. 2) . We created a multivariable regression model in order to elucidate the risk factors associated with the development of AKI. In the model for the entire cohort (Table 3 , model 1), an HbA1c level ≥7% was independently associated with AKI (OR 1.92, 95% CI 1.09-3.36, p = 0.02). Other risk factors associated with CI-AKI included age and the presence of CKD. The Values are presented as mean ± standard deviation or n (%). CAD, coronary artery disease; CPK, creatine phosphokinase; HbA1c, glycated hemoglobin; STEMI, ST segment elevation myocardial infarction. Values are presented as mean ± standard deviation or n (%). AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; sCr, serum creatinine. association of HbA1c level ≥7% with AKI was also maintained in a separate model (Table 3 , model 2) for patients without CKD (OR 2.16, 95% CI 0.97-4.79, p = 0.04). In an analysis performed in the 683 patients who were not critically ill, HbA1c level ≥7% was also independently associated with AKI (OR 2.07, 95% CI 1.08-3.98, p = 0.03).
Discussion
This is the largest trial to date examining the association between HbA1c level and the occurrence of AKI among STEMI patients undergoing primary PCI. Our findings suggest that poor glycemic control (HbA1c ≥7%) was common (about 31%) among these patients and significantly associated with AKI.
Previous reports suggested that acute hyperglycemia was associated with a significant increase in CI-AKI following primary PCI [10, 13] . Marenzi et al. [10] demonstrated similar rates of AKI development following primary PCI in type 2 DM patients with and without admission hyperglycemia. However, development of AKI was more common in nondiabetic patients with admission hyperglycemia compared to those without admission hyperglycemia.
There are several explanations for the relationship between hyperglycemia and deterioration of renal function. The outer medullary region in the kidney is particularly susceptible to ischemic injury because of its high metabolic activity and low prevailing oxygen tension [20] . The partial oxygen pressure of the outer medulla in the kidney is very low during normal function. Contrast media aggravate hypoxic injury to this region by increasing renal vascular resistance [21] . Hyperglycemia may lead to increased production of oxygen free radicals with increased oxidative stress and suppressed flow-mediated vasodilation, inducing medullary hypoxia and ischemia, thus exacerbating the deleterious effect of contrast medium [22, 23] . Furthermore, hyperglycemia may induce osmotic diuresis, resulting in volume depletion and increasing the risk for prerenal azotemia and contrast toxicity.
To date, only a few studies have examined the possible relationship between longstanding poor glycemic control and AKI. Yoshikawa et al. [24] reported a 5% increase in sCr and a decrease of 4 mL/min/1.73 m 2 in eGFR in patients with an HbA1c level ≥6.5% compared to those with an HbA1c level < 6.5% following coronary computed tomography angiography. However, such a small change in the values neither fits the definition of AKI nor does it have any known clinical implications. An elevated HbA1c level (≥7%) was not associated with a higher incidence of CI-AKI compared to an optimal HbA1c level (< 7%) in patients with known type 2 DM undergoing elective coronary angiography [25] . In contrast, elevated HbA1c levels (≥7%) were associated with a higher incidence of CI-AKI compared with optimal HbA1c levels (< 7%) in type 2 DM patients with STEMI treated with primary PCI. However, both of these trials included only a small number of patients with known DM. Moreover, patients having CKD (with an eGFR of ≤60 mL/min/1.73 m 2 ) were excluded, thus the effect of prolonged poor glycemic control on CI-AKI in this population could have not been assessed. Indeed, in the present cohort, patients with CKD and HbA1c ≥7% had a ten-fold increase in the incidence of AKI compared to patients with HbA1c < 7% and no CKD, while the detrimental effect of long-term hyperglycemia was maintained after adjustment for the presence of CKD.
The results of the present study might be explained with the long and more marked effect of long-standing hyperglycemia on intrarenal mechanisms. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction [26] . Other changes in intraglomerular hemodynamics include local activation of the renin-angiotensin system, biochemical derangements, proteinuria, and hypoxia in addition to the direct effect of hyperglycemia [27] .
Our findings bear some important clinical implications. Among patients undergoing PCI, especially if nonemergent, HbA1c levels ≥7% may point out those at high risk for CI-AKI and warrant prophylactic renal protection [28] [29] [30] . In addition, as 12% of patients without known DM had HbA1c ≥7%, it appears that a significant proportion of patients with an acute coronary syndrome may have occult type 2 DM. It appears that measurement of HbA1c levels should be considered, regardless of history of type 2 DM.
We acknowledge several important limitations of our study. This was a single-center retrospective and nonrandomized observational study and may have been subject to bias, even though we included consecutive patients and attempted to adjust for confounding factors using the multivariable regression model. The diagnosis of DM was considered if it had been previously diagnosed by a physician or if patients received medication to lower blood glucose levels. However, as some patients without known DM had elevated HbA1c levels, some of these nondiabetic patients actually had undiagnosed DM. The definition of the Acute Kidney Injury Network criteria refers to sCr change within a time frame of 48 h. As the change in sCr can lag beyond this period due to delayed effects of contrast medium and drug, worsening of renal function might have occurred following hospital discharge in some patients, thus the true incidence of CI-AKI described in our study may have been underestimated. No information was present regarding the amount pf postprocedural intravenous fluid the patients received. In addition, information on left ventricular end-diastolic pressure during cardiac catheterization, which would also help determine the fluid status of patients at time of acute STEMI, was not available as this is not performed routinely in our catheterization laboratory during primary PCI. Finally, as data regarding concomitant renin/angiotensin blockers and diuretics throughout hospitalization was not present in many patients, their effect on AKI development could not be assessed.
No information was present regarding the distribution of contrast medium between patients, thus sensitivity analysis to see whether the type of contrast medium affected the result could have not be performed. Patients without information regarding HbA1c levels (not included in the present analysis) had less comorbidities, a fact which could have affected the rate of AKI reported.
In conclusion, in the present analysis we found that a HbA1c level ≥7% was associated with a higher likelihood for AKI in STEMI patients treated with primary PCI.
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